SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

NCT00442572 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: PEGASYS [peginterferon alfa-2a]

Sponsor

Hoffmann-La Roche